CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 ---- Advancing four clinical programs for ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

Genetic testing for hereditary arrhythmia and cardiomyopathy in an area with known founder effects on local genetic variants had a high yield in identification of pathogenic variants by taking into ...

University of Florida researchers developed PhyloFrame, a machine-learning tool that uses artificial intelligence to account for ancestral diversity in genetic data.

Most individuals diagnosed with a rare disease won’t live to become teenagers or adults. I knew what I had to do.

This €1.6 Million financing will allow MSInsight to finalize MSIcare's technological development, demonstrate its performance ...

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...

University of Florida researchers are addressing a critical gap in medical genetic research—ensuring it better represents and ...

These models can interpret complex medical data, genomic sequences, and cellular interactions, making AI a powerful tool in ...

Beam Therapeutics reports Phase 1/2 trial data showing BEAM-302's potential in AATD treatment, with dose-dependent mutation correction and sustained effects.

Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025Dosing ...

Generative AI combined with ElevateBio Life Edit's immense library of CRISPR systems and proprietary data from experiments will drive the synthesis and optimization of novel CRISPR drugs for genetic ...